A case of fatal interstitial pneumonia during treatment of radiotherapy plus cetuximab for patient with head and neck carcinoma

Numico G, Silvestris N, Grazioso Russi E (2011) Advances in EFGR-directed therapy in head and neck cancer. Front Biosci (Schol Ed) 3:454–466

Ishiguro M, Watanabe T, Yamaguchi K et al (2012) A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 42:287–294

Chua W, Peters M, Loneragan R et al (2009) Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 8:118–120

NCCN clinical practice guidelines in oncology. Glottic larynx. version 1.2014. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf . Accessed 1 Feb 2014

Kato T (2013) Head and neck medical treatment guidelines (in Japanese). Kanehara, Tokyo, pp 27–32

Ikarashi F, Nonomura N, Nakano Y (1990) Clinical study on laryngeal cancer. Nippon Jibiinkoka Gakkai Kaiho 93:772–778

Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

Lai JI, Wang WS, Lai YC et al (2010) Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy. Int J Clin Pharmacol Therapeut 48:425–428

Inoue A, Saijo Y, Maemondo M et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137–139

Perri F, Ionna F, Pavone E et al (2013) Treatment approaches in elderly patients with head and neck cancer. Anti-Cancer Agents Med Chem 13:1383–1390

Shioiri M, Hasegawa M, Tanaka H et al (2012) Two cases of interstitial pneumonia caused by cetuximab plus mFOLFOX6 therapy in metastatic colorectal cancer patients. Gan To Kagaku Ryoho 39:2198–2200

Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial Lung Disease in Japanese Patients with Lung Cancer. Am J Respir Crit Care Med 177:1348–1357

Shi L, Tang J, Tong L et al (2014) Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83:231–239